Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Acute myocardial infarction related gene SERPINB13 and application thereof

An acute myocardial infarction and genetic technology, applied in the field of biomedicine, achieves good application prospects, good stability, and rapid response effects

Active Publication Date: 2016-02-24
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF1 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The inventor performed high-throughput sequencing on the blood samples of 6 cases of acute myocardial infarction and 6 control groups, combined with bioinformatics methods for gene screening, and selected the highly expressed candidate gene SERPINB13 among the genes with obvious differential expression. There is no report related to SERPINB13 and acute myocardial infarction. Further, the inventors carried out molecular verification and confirmed that SERPINB13 is highly expressed in the acute myocardial infarction group, and SERPINB13 inhibitors can be used to prepare drugs for the treatment of acute myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Acute myocardial infarction related gene SERPINB13 and application thereof
  • Acute myocardial infarction related gene SERPINB13 and application thereof
  • Acute myocardial infarction related gene SERPINB13 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The collection of embodiment 1 case

[0029] From December 2012 to June 2014, 6 patients with initial acute myocardial infarction in the Department of Cardiovascular Medicine of the hospital were selected. The time from the onset of acute myocardial infarction to admission was 0.5-10 hours. The inclusion criteria were in line with the inclusion criteria for acute myocardial infarction announced at the 2012 ESC Congress. All enrolled patients have signed the informed consent. The healthy controls were 6 healthy subjects from the physical examination center of the hospital, who matched the age and gender of the patients in the experimental group, and related diseases were excluded according to the exclusion criteria of the AMI group. Healthy subjects informed and agreed to participate in the study.

[0030] Inclusion criteria:

[0031] Refer to the new version of the global unified definition of myocardial infarction diagnostic criteria announced at the ESC Conference ...

Embodiment 2

[0051] Example 2 High-throughput sequencing and analysis

[0052] RNA extraction is performed on peripheral blood, followed by agarose gel electrophoresis after RNA extraction. From the results of electrophoresis, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome sequencing. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2. The qualified samples were sent to the sequencing company for sequencing. The sequencing platform was the HiSeq2500 high-throughput sequencing platform of Illumina Company for high-throughput transcriptome deep sequencing. The sequencing company provided the data analysis results and combined with the literature, we screened the differentially expressed gene SERPINB13.

Embodiment 3

[0053] Example 3 Expression of SERPINB13 gene in peripheral blood of acute myocardial infarction group and control group

[0054] 1. Materials and methods

[0055] 1. Materials

[0056] The peripheral blood of 48 cases of patients with acute myocardial infarction and 45 cases of control group were selected and grouped and numbered. The inclusion and exclusion criteria of the two groups refer to Example 1.

[0057] 2. Method

[0058] 2.1 Extraction of peripheral blood RNA in patients with acute myocardial infarction and controls

[0059] leukapheresis

[0060] (1) Take 2m1 anticoagulated peripheral blood (blood collection time does not exceed 3h);

[0061] (2) Add an equal volume of sterile PBS to the peripheral blood and mix thoroughly to form a cell suspension;

[0062] (3) Add 4ml of lymphocyte separation solution to another centrifuge tube;

[0063] (4) Pipette 4m1 of the cell suspension and gently add it to the surface of the lymphocyte separation medium along the t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to acute myocardial infarction related gene SERPINB13 and an application thereof. Through research, the inventor finds that the gene SERPINB13 has high expression in the peripheral blood of a patient suffering from the acute myocardial infarction, and meanwhile, the inventor designs interference RNAs of SERPINB13, wherein the interference RNAs can effectively inhibit the expression of the gene SERPINB13, and can be used for preparing the medicines for treating the acute myocardial infarction. With the adoption of the acute myocardial infarction related gene SERPINB13 and the application thereof, a novel solution is provided, and great application values are achieved.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the acute myocardial infarction related gene SERPINB13 and its application. Background technique [0002] In recent years, with the change of living environment and lifestyle and the acceleration of population aging process, coronary atherosclerotic heart disease has become one of the diseases that seriously endanger human health. Especially the most serious clinical type of coronary atherosclerotic heart disease—acute myocardial infarction (Acute Myocardial Infarction, AMI). How to reduce the incidence and mortality of coronary heart disease and acute myocardial infarction, improve the quality of life of patients with coronary heart disease, and reduce the economic burden of individuals and society has become a major problem in the medical field. With the completion of the Human Genome Project and the development of gene chip technology, many causative genes of single-gene diseases h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/68A61K45/00A61K48/00A61K31/7088A61K38/00A61P9/10
CPCA61K31/7088A61K38/00A61K45/00A61K48/005C12Q1/6883G01N33/6893G01N2800/324
Inventor 任静王晓云杨承刚
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com